Indian botanical extracts manufacturer Arjuna Natural is investing $1.5m in a clinical research programme to explore the health benefits of its turmeric curcumin.
The investment is more than 10% of its total turnover in the research on its new healthy ingredients to be launched this year.
Universities and institutes across India, Australia, Italy, the US and Japan, are conducting research on Arjuna’s all-natural curcumin, BCM-95.
At least 12 clinical studies are being carried out to evaluate the efficacy of turmeric curcumin in treating depression, Alzheimer’s disease and cancer, among others.
Arjuna holds 12 patents for BCM-95 worldwide, with several additional patents pending.
Arjuna joint managing director Benny Antony said: "We differentiate our turmeric curcumin through a practice of extensive research and development.
"BCM-95 is the most researched bioavailable curcumin on the market, with a majority share in the US."
Arjuna claims that its curcumin, produced in the company’s own facility, is highly bioavailable.
The patented formulation method involves extracting the maximum amount of free curcumin, without synthetic additives.
Antony added: "Arjuna meets the new European 2015/1933 PAH regulation that sets maximum levels of PAHs in food supplements.
"This bioactive ingredient is clean of pesticides and heavy metals. Arjuna invested in the most advanced quality control equipment to meet the new EU regulations, and to ensure all products are clean and safe. The growing global demand for curcumin, and consumer expectations of pure formulations, encouraged Arjuna to develop a clean, GMO-free ingredient that consumers can trust."
Image: Arjuna Natural is investing $1.5m in turmeric curcumin research. Photo: courtesy of PRNewsFoto / Arjuna Natural.